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ABSTRACT
Diacylglycerol acyltransferase-1 (DGAT1) is involved in the assembly of hepatitis C virus (HCV) by facilitating the trafficking of
the HCV core protein to the lipid droplet. Here, we abrogated DGAT1 expression in Huh-7.5 cells by using either the transcrip-
tion activator-like effector nuclease (TALEN) or lentivirus vector short hairpin RNA (shRNA) and achieved complete long-term
silencing of DGAT1. HCV entry was severely impaired in DGAT1-silenced Huh-7.5 cell lines, which showedmarkedly dimin-
ished claudin-1 (CLDN1) expression. In DGAT1-silenced cell lines, the forced expression of CLDN1 restored HCV entry, imply-
ing that the downregulation of CLDN1 is a critical factor underlying defective HCV entry. The expression of the gene coding for
hepatocyte nuclear factor 4 (HNF4) and other hepatocyte-specific genes was also reduced in DGAT1-silenced cell lines. After
DGAT1 gene rescue, CLDN1 expression was preserved, and HCV entry was restored. Strikingly, after DGAT1 silencing, CLDN1
expression and HCV entry were also restored by low-dose palmitic acid treatment, indicating that the downregulation of CLDN1
was associated with altered fatty acid homeostasis in the absence of DGAT1. Our findings provide novel insight into the role of
DGAT1 in the life cycle of HCV.
IMPORTANCE
In this study, we report the novel effect of complete silencing of DGAT1 on the entry of HCV. DGAT1 was recently reported as a
host factor of HCV, involved in the assembly of HCV by facilitating the trafficking of the HCV core protein to lipid droplets. We
achieved complete and long-term silencing of DGAT1 by either TALEN or repeated transduction of lentivirus shRNA.We found
that HCV entry was severely impaired in DGAT1-silenced cell lines. The impairment of HCV entry was caused by CLDN1 down-
regulation, and the expression of HNF4 and other hepatocyte-specific genes was also downregulated in DGAT1-silenced cell
lines. Our results suggest new roles of DGAT1 in human liver-derived cells: maintaining intracellular lipid homeostasis and af-
fecting HCV entry by modulating CLDN1 expression.
Hepatitis C virus (HCV) infection poses a major threat to hu-man health, with a prevalence of more than 160 million peo-
ple worldwide (1). In addition to a combination regimen of pegy-
lated interferon alpha (IFN-) and ribavirin, drugs acting directly
on HCV have now been developed, although these direct-acting
antivirals may prompt the emergence of resistant strains (2, 3).
Our increasing understanding of the HCV-host interactions is
allowing novel therapeutic approaches to be developed that mod-
ulate host factors that are required for viral entry, replication, and
egress; these factors may have a higher genetic barrier to viral
resistance (4).
Diacylglycerol acyltransferase-1 (DGAT1) is one of two known
DGAT enzymes catalyzing the final step in triglyceride biosynthe-
sis (5, 6). The expression of DGAT1 and its physiologic role differ
in humans and mice. In mice, DGAT1 is expressed in many or-
gans, including the skeletal muscle, heart, and intestines, but it is
barely expressed in the liver (5). Because DGAT1-deficient mice
are resistant to diet-induced obesity (7), pharmacological DGAT1
inhibitors are being developed for the treatment of metabolic dis-
eases (8). In contrast to mice, human DGAT1 is mainly expressed
in the small intestine and liver (9). Human DGAT1 reesterifies
partial glycerides to triglycerides using exogenous fatty acids. In
addition, intracellular lipid homeostasis is dysregulated in human
hepatocytes in the absence of DGAT1 (10).
As a host factor interacting with HCV, DGAT1 has drawn at-
tention for its role in trafficking the HCV core protein to lipid
droplets (11). In addition, the same study reported that treatment
with a DGAT1 inhibitor blocked the association of the HCV core
protein with lipid droplets and decreased the production of infec-
tious HCV virions (11). Further research has demonstrated that
DGAT1 is involved in the localization of theHCVNS5Aprotein to
lipid droplets and promotes NS5A interaction with the HCV core
protein (12). However, in these reports, DGAT1 inhibitors were
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mainly used to block DGAT1 activity, and the observation was
limited to as late as 72 h after treatment with DGAT1 inhibitors.
In the present study, we investigated the effects of complete,
long-term silencing of DGAT1 on the whole life cycle of HCV.We
established DGAT1 knockdown cell lines and a DGAT1 knockout
(KO) cell line and observed that the entry of HCV into DGAT1-
silenced cells was impaired. Furthermore, we identified the under-
lying mechanism of defective HCV entry into these cell lines.
MATERIALS AND METHODS
Cell culture.Huh-7.5 cells (Apath, LLC, Brooklyn, NY) (13), HepG2 cells
(ATCC,Manassas, VA), Caco-2 cells (ATCC,Manassas, VA), and 293TN
cells (System Biosciences, Mountain View, CA) were maintained at 37°C
with 5%CO2 in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum (WelGENE, Daegu, South Korea), 4.5 g/liter glu-
cose, L-glutamine, and 1% penicillin-streptomycin (Invitrogen, Carlsbad,
CA). Short hairpin RNA (shRNA)-transduced cells were maintained in
complete medium containing 1 g/ml puromycin (Sigma-Aldrich, St.
Louis,MO), and shRNA-resistant DGAT1-transfected cells were cultured
in completemedium thatwas supplementedwith 1g/ml puromycin and
1 mg/ml G418 (A.G. Scientific, San Diego, CA). All of the transfections
were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
Generation and infection of JFH-1 HCVcc. The Japanese fulminant
hepatitis 1 (JFH-1) strain (genotype 2a) (14) of cell-culture-derived HCV
(HCVcc) (15–17) was generated and propagated as previously de-
scribed (18). For the titration of HCV infectivity, a colorimetric focus-
forming assay was performed as previously described (19). Cell cul-
tures were inoculated with JFH-1 HCVcc at a multiplicity of infection
(MOI) of 0.1 to 0.5.
HCVpp entry assay. For the evaluation of HCV entry, HCV pseudop-
articles (HCVpp)with E1 and E2 glycoproteins of variousHCVgenotypes
(H77, genotype 1a; TH, genotype 1b; JFH-1, genotype 2a; and J6CF, ge-
notype 2a) were generated, and cell cultures were inoculated as previously
described (20, 21). Virus pseudoparticles with vesicular stomatitis virus
glycoproteins (VSV-G) were used as positive controls.
Preparation and transduction of shRNA-DGAT1-expressing lenti-
viruses. Three bacterial glycerol stocks with lentiviral shRNA constructs
expressing validated sequences of DGAT1 (shRNA-DGAT1) and one
stock with lentiviral constructs expressing validated sequences of DGA2
(shRNA-DGAT2) were purchased from Sigma-Aldrich. The sequences
that are recognized by these shRNAs are presented in Fig. S1 in the sup-
plemental material. A control shRNA vector (shRNA-control) encoding a
scrambled sequence was also prepared. Lentiviral vectors comprising
VSV-G plasmid, gag-pol plasmid, and a MISSION shRNA plasmid were
transfected into 293TN cells using Lipofectamine 2000 (Invitrogen). After
48 h of transfection, lentiviral particles were harvested, passed through a
0.45-m-pore syringe filter, concentrated with WelProt virus concentra-
tion reagent (WelGENE), and stored at 70°C. To maximize transduc-
tion efficiency, cells were repeatedly transduced with concentrated lenti-
virus. After 48 h of transduction, the cells were treated with 1 g/ml
puromycin and expanded over 3 to 6 weeks in puromycin-containing
selection medium until they showed a stable phenotype. For the forced
expression of CLDN1, shRNA-DGAT1-transduced cell lines were trans-
fectedwith a plasmid-encodingCLDN1 gene cloned fromHuh-7 cells and
regulated by an EF-1 promoter.
Generation of DGAT1-KO cell line using TALEN. The target se-
quence of the DGAT1-targeting transcription activator-like effector nu-
clease (TALEN) was TGCCATCGCCTGCAGGATTC (left)-TTTATTCA
GCTCT (spacer)-GACAGTGGCTTCAGCAACTA (right). The plasmid
encoding DGAT1-targeting TALEN was prepared as recently described
(22) and provided by Toolgen, Seoul, Republic of Korea (http://www
.talenlibrary.net/) (order no. H157465). Huh-7.5 cells were cotransfected
with a total of 8 g DNA comprising 2 g of plasmid encoding one
member of the DGAT1-targeting TALEN, 2 g of plasmid encoding an-
other member of the TALENs, and 4 g of the reporter encoding H-2Kk
(23) via electroporation using the InvitrogenNeon transfection system (at
a voltage of 1,100 V for 30 ms, using a 100-ml tip and one pulse). The
transfected cells were cultured for 1 day at 37°C and for 2 days at 30°C
(cold shock) (24) and subjected to magnetic separation as previously de-
scribed (23). Briefly, trypsinized cells were mixed with magnetic bead-
conjugated antibodies against H-2Kk (MACSelect Kk microbeads; Milte-
nyi Biotech,Germany) and incubated for 20min at 4°C. Labeled cells were
separated using aMACS LS column (Miltenyi Biotech). The DGAT1mu-
tant cells that were enriched by this magnetic separation were plated into
96-well plates at a density of 0.25 cell/well. Two weeks after plating, only
single-cell-derived colonies of a circular shape were manually selected
under a microscope. Genomic DNA was isolated using the DNeasy blood
and tissue kit (Qiagen, Valencia, CA). We analyzed 62 single-cell-derived
colonies using the T7E1 enzyme digestion assay, which selectively detects
heteroduplex DNA that results from gene editing by TALEN. We also
analyzed these colonies by sequencing. The region of the DGAT1 gene
containing the TALEN target site was amplified by nested PCR (primer
sequence, 1st PCR, forward, 5=-CAAGCTCCATGTAGGTCCAG-3=, and
reverse, 5=-CTCTCCTGGGATCCAATG-3=; 2nd PCR, forward, 5=-TCT
GACCCTGACATGCTCGT-3=, and reverse, 5=-CCAATGGGAAGCAGC
AAGTA-3=), cloned into the T-Blunt vector, and sequenced.
Flow cytometry. For the detection of HCV receptors on the cell sur-
face, the following antibodies were used: phycoerythrin (PE)-conjugated
mouse monoclonal anti-CD81 IgG1 (clone JS-81; BD Biosciences, San
Jose, CA), mouse monoclonal anti-CLDN1 (clone 7A5; developed by
DNA immunization of the CLDN1 expression construct), rabbit poly-
clonal anti-SR-B1 (clone H-180; BD Biosciences), and rabbit polyclonal
anti-occludin (anti-OCLN) (Sigma-Aldrich). For the staining of OCLN,
the cells were fixed and permeabilized using the Foxp3 staining kit
(eBioscience, San Diego, CA). PE-conjugated goat anti-rabbit IgG
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used as a sec-
ondary antibody for the SR-B1 and OCLN staining. For the intracel-
lular staining of DGAT1, mouse monoclonal anti-DGAT1 IgG1 (A-5;
Santa Cruz Biotechnology, Inc.) was used as a primary antibody, and
allophycocyanin (APC)-conjugated anti-mouse IgG (BD Biosciences)
was used as a secondary antibody. For the intracellular staining of the
HCV core protein, mouse monoclonal anti-HCV core IgG1 (clone
C7-50; Thermo Scientific/Affinity BioReagents, Rockford, IL) was
used as a primary antibody, and fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG1 (clone A85-1; BD Biosciences) was used
as a secondary antibody. For the intracellular staining, the cells were
fixed and permeabilized using the Foxp3 staining kit (eBioscience) and
then stained with the primary antibody for 20 min at 4°C. After a
washing step with permeabilization buffer (eBioscience), the cells were
stained with the appropriate secondary antibodies. The LSR II instru-
ment (BD Biosciences) was used for the flow cytometry. The FlowJo
software (TreeStar, Ashland, OR) was used for data analysis.
Immunoblots.Cell lysates were prepared, and 20g of each lysate was
loaded onto SDS-PAGE gels and analyzed by immunoblotting. The anti-
bodies that were used for the immunoblots were as follows: mouse
monoclonal anti-DGAT1 IgG1 (clone A-5; Santa Cruz Biotechnology,
Inc.), rabbit polyclonal anti-DGAT1 (H-255; Santa Cruz Biotechnology,
Inc.), rabbit polyclonal anti-DGAT2 (Sigma-Aldrich), rabbit polyclonal
anti-CLDN1 (Abcam, Cambridge, United Kingdom), rabbit polyclonal
anti-hepatocyte nuclear factor 4 (anti-HNF4) (H-171; Santa Cruz
Biotechnology, Inc.), and mouse monoclonal anti-tubulin (clone B-5-
1-2; Sigma-Aldrich). Following the blotting, the membrane was incu-
bated with primary antibodies (diluted at 1:200 to 1:1,000) overnight
at 4°C or for 1 h at room temperature. The signal was detected using the
horseradish peroxidase-conjugated secondary antibody (Jackson Immuno
Research Laboratories, West Grove, PA) with enhanced chemiluminescence
reagents (GEHealthcare/Amersham, Buckinghamshire, United Kingdom).
Confocal microscopy. The antibodies that were used for the confocal
microscopy imaging were as follows: mouse monoclonal anti-claudin-1
(anti-CLDN1) (clone 1C5-D9; Abcam), rabbit polyclonal anti-occludin
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(Invitrogen), Cy3-conjugated goat anti-mouse IgG (Jackson Immuno
Research Laboratories,West Grove, PA), and Alexa Fluor 488-conjugated
donkey anti-rabbit IgG (BioLegend, San Diego, CA). The cells were fixed
with 4% paraformaldehyde for 20min and permeabilized with 0.5% (vol/
vol) Triton X-100 for 10 min. The slides were incubated with primary
antibodies (diluted at 1:100) for 3 h at room temperature. After being
washed with phosphate-buffered saline three times, they were incubated
with secondary antibodies (diluted at 1:1,000). Following the addition of
mounting solution, images were acquired using an LSM-510 confocal
laser-scanning microscope (Carl Zeiss, Jena, Germany).
Intracellular lipid droplet quantification. Cells were fixed with 2%
paraformaldehyde for 20min on slides and permeabilizedwith 0.5% (vol/
vol) Triton X-100 for 10 min. The slides were incubated in phosphate-
buffered saline (PBS) containing 10 M BODIPY (boron-dipyr-
romethene) lipid probe 493/503 (Invitrogen) for 1 h at room temperature.
After the addition of mounting solution, images were acquired using an
LSM-510 confocal laser-scanning microscope (Carl Zeiss). For the flow
cytometry analysis, control and DGAT1-silenced cells were pelleted and
resuspended in fluorescence-activated cell sorter (FACS) buffer (PBSwith
2% fetal bovine serum [FBS], 2 mM EDTA). Then, cells were fixed and
permeabilized using a Foxp3 staining kit (eBioscience). After permeabili-
zation, the cells were resuspended with FACS buffer containing 10 M
BODIPY lipid probe 493/503 and incubated for 30 min in the dark. Next,
the cells were washed in FACS buffer, pelleted, and resuspended in FACS
buffer. Up to 50,000 events were detected using the LSR II instrument (BD
Biosciences) for flow cytometry. FlowJo software (TreeStar) was used for
the data analysis.
RNA extraction, cDNA synthesis, and real-time qPCR.Total RNA
isolation, cDNA synthesis, and TaqMan real-time quantitative PCR
(qPCR) were performed as previously described (18). In brief, total RNA
was isolated with the RNeasy minikit (Qiagen), and cDNA was synthe-
sized using an Applied Biosystems high-capacity cDNA synthesis kit (Ap-
plied Biosystems, Foster City, CA). TaqMan gene expression assays (Ap-
plied Biosystems) were used to determine the mRNA levels of the target
genes. For the titration of intracellular HCVRNA copies, the sequences of
the primers and probes that were used are as follows (25): forward, CGG
GAG AGC CAT AGT GG-3; reverse, AGT ACC ACA AGG CCT TTC G;
and probe, 6-carboxyfluorescein (FAM)-CTGCGGAACCGGTGAGTA
CAC-6-carboxytetramethylrhodamine (TAMRA). The results were stan-
dardized to an endogenous control, -actin.
Palmitic acid treatment and cell culture.Cells were incubated inme-
dium containing 10% charcoal-stripped fetal bovine serum (WelGENE)
that was supplemented with 50 M palmitic acid (Sigma-Aldrich) or
dimethyl sulfoxide (DMSO) in complexeswith 1%bovine serumalbumin
(BSA). The medium was changed every 2 days for the continuous treat-
ment.
Cell proliferation and viability assay. The cell proliferation activities
were assessed using the BD Biosciences apoptosis, DNA damage, and cell
proliferation kit according to the manufacturer’s protocol. A 1 mM con-
centration of bromodeoxyuridine (BrdU) was incorporated into the con-
trol andDGAT1-silenced cell lines for 3 h. For the flow cytometry analysis,
control andDGAT1-silenced cells were pelleted and resuspended in FACS
buffer. Then, the cells were fixed and permeabilized, treated with DNase,
stained with peridinin chlorophyll protein (PerCP)-Cy5.5-conjugated
mouse anti-BrdU (BDBiosciences), and incubated for 30min in the dark.
Next, cells were washed in FACS buffer, pelleted, and resuspended in
FACS buffer. Up to 50,000 events were detected using the LSR II instru-
ment (BD Biosciences). FlowJo software (TreeStar) was used for the data
analysis. For the cell viability assay, the cells were fixed and permeabilized,
stained with PE-conjugated mouse anti-cleaved poly(ADP-ribose) poly-
merase (PARP) (Asp214) antibody, and incubated for 30min in the dark.
Data were obtained using the LSR II instrument (BD Biosciences).
ChIP. Chromatin immunoprecipitation (ChIP) assays were per-
formed according to the manufacturer’s instructions (Pierce agarose
ChIP kit; Pierce, Rockford, IL). Approximately 1 106 cells were used for
each immunoprecipitation. Whole-cell lysates were immunoprecipitated
using 1 g of rabbit anti-HNF4 (H171) (Santa Cruz Biotechnology,
Inc.) or IgG. Real-time qPCR was used to amplify the region near the
HNF4 binding site in the promoter of the CLDN1 gene (26, 27). Reac-
tions were performed in triplicate in three independent experiments, and
the means were normalized to 1% of the chromatin input.
Statistical analyses.Data are presented asmeans standard errors of
the means (SEM). Unpaired t tests or two-tailed Mann-Whitney U tests
were performed. All of the statistical analyses were conducted using
GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA). A P
value of0.05 was considered statistically significant.
RESULTS
Establishment of DGAT1-silenced Huh-7.5 cell lines using ei-
ther TALENor lentivirus vector shRNA.To identify the effects of
complete, long-term silencing of DGAT1 on the whole life cycle of
HCV in Huh-7.5 cells, we knocked down DGAT1 expression by
lentivirus vector shRNA transduction or knocked out theDGAT1
gene using a pair of TALENs in these cells. Three stable cell lines
(shRNA-DGAT1-1666, shRNA-DGAT1-1183, and shRNA-DGAT1-
1402) were established by the repeated transduction of three dif-
ferent lentiviruses carrying shRNA (see Fig. S1 in the supplemen-
tal material) and expanded in puromycin-containing selection
medium formore than 2months. For themore complete silencing
of DGAT1 without residual expression, we established a DGAT1-
knockout cell line (DGAT1-TALEN) using TALENs. To isolate
cells in which the TALEN-knocked out DGAT1, we transfected
Huh-7.5 cells with plasmids encoding a pair of DGAT1-targeting
TALENs in combination with a reporter plasmid. The reporter
plasmid expressed H-2Kk when a pair of DGAT1-targeting
TALENs functioned successfully in the transfected cells. After
transfection, we selected H-2Kk-expressing cells using magnetic
bead-conjugated anti-H-2Kk antibodies. We analyzed 62 single-
cell-derived colonies using a T7E1 enzyme digestion assay, which
selectively detects heteroduplex DNA resulting from gene editing
by TALEN (Fig. 1A), and then we chose a DGAT1-knockout cell
line harboring a shifted open reading frame or premature stop
codon in the DGAT1 gene (Fig. 1B). In the cell lines with DGAT1
that was silenced by either shRNA or TALEN, we verified the loss
of DGAT1 expression at both the mRNA and protein levels. The
expression of DGAT1 mRNA in the shRNA-DGAT1-transduced
cell lines was less than 20% of that in a control cell line (shRNA-
control), and DGAT1 mRNA was not detected in the DGAT1-
TALEN cell line (Fig. 1C). The DGAT1 protein was deficient in all
of the DGAT1-silenced cell lines (Fig. 1D).
We compared several basic characteristics of the DGAT1-si-
lenced cell lines with those of the control cell line. For example,
triglyceride-rich intracellular lipid droplets were barely detectable
in the DGAT1-silenced cell lines, whereas they were abundant in
the control cell line (Fig. 1E). Cell proliferation and apoptosiswere
also analyzed by BrdU incorporation and cleaved PARP staining,
respectively. Cell proliferation rates were higher in the DGAT1-
silenced cell lines than in the control cell line, whereas apoptotic
death was not altered (data not shown).
HCV entry is impaired in DGAT1-silenced Huh-7.5 cell
lines. To identify the effects of DGAT1 silencing on the whole life
cycle of HCV, we inoculated DGAT1-silenced Huh-7.5 cell lines
with JFH-1 cell culture-produced HCV (HCVcc) and measured
infectious virions in the culture supernatants. In accordance with
the role ofDGAT1 in the assembly ofHCV, infectious virionswere
not detected in the culture supernatants of the DGAT1-silenced
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cells (Fig. 2A). We also quantified intracellular HCV RNA copies
and unexpectedly discovered that the intracellularHCVRNA titer
was very low in the DGAT1-silenced cell lines (Fig. 2B). Following
inoculation of the DGAT1-silenced cell lines with a higher dose of
JFH-1, we detected no intracellular HCV core protein by flow
cytometry (Fig. 2C).
Next, we transfected the control andDGAT1-silenced cell lines
with JFH-1 RNA. As expected from the previous study (11) and
loss of intracellular lipid droplets in theDGAT1-silenced cell lines,
the production of infectious virions was severely impaired in the
DGAT1-silenced cell lines (Fig. 2D). The intracellular HCV RNA
copy number was also lower in theDGAT1-silenced cell lines than
in the control cell line, with a difference of less than 1 log (Fig. 2E),
indicating that HCV RNA replication is slightly impaired in
DGAT1-silenced cells. However, thisminor decrease is in contrast
to the enormous decrease that was observed in the HCVcc inocu-
lation study (Fig. 2B). This finding indicates that another factor is
the major cause of the very low intracellular HCV RNA levels in
HCVcc-inoculated, DGAT1-silenced cells.
With the hypothesis that HCV entry is defective in DGAT1-
silenced cell lines, we evaluated HCV entry using HCVpp of var-
ious genotypes. NoHCVpp entered theDGAT1-silenced cell lines
(Fig. 2F), whereas the control virus pseudoparticles with VSV-G
did enter these lines, indicating that HCV entry is impaired in the
absence of DGAT1.
Claudin-1 expression is downregulated in DGAT1-silenced
cell lines. Because of the impaired HCV entry into DGAT1-si-
lenced cell lines, we investigated the expression of host proteins
participating in HCV entry, including tetraspanin CD81 (28), the
high-density lipoprotein receptor scavenger receptor class B type I
(SR-BI) (29), and two tight junction proteins, claudin-1 (CLDN1)
(30) and occludin (OCLN) (31). In the flow cytometric analysis,
the expression of CD81, SR-BI, and OCLN in DGAT1-silenced
cell lines was well preserved, but that of CLDN1 was markedly
diminished (Fig. 3A and B). We observed the downregulation of
CLDN1 expression at the mRNA level by real-time quantitative
PCR (Fig. 3C). Immunoblotting confirmed the downregulation of
CLDN1 expression (Fig. 3D). Notably, CLDN1 expression was
FIG 1 Establishment of DGAT1-silenced cell lines using DGAT1-TALEN or lentivirus vector shRNA DGAT1. (A) Huh-7.5 cells were transfected with plasmids
encoding a pair ofDGAT1-targeting TALENs in combinationwith the reporter encodingH-2Kk. After themagnetic sorting of cells with TALEN-drivenmutations, we
analyzed 62 single-cell-derived colonies using the T7E1 assay. The region of the DGAT1 gene containing the TALEN target site was amplified by nested PCR and
visualizedbyagarose gel electrophoresis.Representativedata fromtheT7E1assay arepresentedhere.Circlednumbers indicate clones thatwere selected forDGAT1gene
sequencing. (B)DNAsequences of theDGAT1-TALENcell line. The sequence presentedhere is part of theDGAT1 gene of clone 13, one of the clones that are presented
in panel A. Zinc finger nuclease recognition sites are underlined, and deleted bases are indicated by dashes. TGA, the premature stop codon, is shaded in gray. Clone 13
has a shifted open reading frame (ORF) or premature stop codon in the DGAT1 gene. (C) DGAT1 mRNA levels were determined by real-time quantitative PCR in
DGAT1-silenced cell lines and standardized to -actin mRNA levels (n 	 3). N.D., not detected. (D) DGAT1 protein expression in DGAT1-silenced cell lines was
assessed by immunoblotting. (E) Intracellular lipid droplet stainingwas performedusing theBODIPY lipid probe 493/503 in the control andDGAT1-silenced cell lines.
The scale bar represents 20m. The right panel represents flow cytometry analyses of the same cell lines.
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FIG 2 HCV entry into DGAT1-silencedHuh-7.5 cell lines is impaired. (A and B) DGAT1-silenced cell lines were inoculated with JFH-1HCVcc at a multiplicity
of infection (MOI) of 0.1. After 72 h, infectious HCV virions were quantified in culture supernatants by a colorimetric focus-forming assay (19). The data are
presented as focus-forming units (FFU) perml of culture supernatant (n	 3) (A). Intracellular HCVRNA levels were determined by real-time quantitative PCR
and standardized to-actinmRNA levels (n	 3) (B). (C)DGAT1-silenced cell lineswere inoculatedwith JFH-1HCVcc at anMOI of 0.5. After 60 h, intracellular
HCV core proteins were detected by flow cytometry. Data are representative of two independent experiments. (D and E) DGAT1-silenced cell lines were
transfected with 5g in vitro-transcribed JFH1 RNA. After 72 h, infectious HCV virions were quantified in culture supernatants by a colorimetric focus-forming
assay (19). The data are presented as focus-forming units (FFU) per ml of culture supernatant (n	 3) (D). Intracellular HCV RNA levels were determined by
real-time quantitative PCR and standardized to -actin mRNA levels (n 	 3) (E). (F) HCV entry into DGAT1-silenced cell lines was assessed using HCVpp
harboring E1 and E2 glycoproteins of various HCV genotypes. Virus pseudoparticles harboring the vesicular stomatitis virus G (VSV-G) envelope glycoprotein
were used as a positive control. HCVpp entry was determined by luciferase activity. Data are expressed as percentages of the shRNA-control cell line (n	 3). Bar
graphs represent means SEM. *, P 0.001 compared to the control. N.D., not detected.
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FIG 3 CLDN1 expression is downregulated in DGAT1-silenced cell lines. (A and B) The expression of CD81, SR-B1, CLDN1, and OCLN in DGAT1-silenced
cell lines was analyzed by flow cytometry. Histograms are representative of three independent experiments (A), and the mean fluorescence index (F/F0) of the
Sung et al.
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not downregulated by the silencing of DGAT2, the other DGAT
protein present in human hepatocytes (Fig. 3E). Immunofluores-
cence staining revealed that CLDN1 expression on the cell mem-
brane was lost in theDGAT1-silenced cells (Fig. 3F). Additionally,
a significant proportion ofOCLNwas localized not only to the cell
membrane but also to the cytoplasm in these cells (Fig. 3F). We
further confirmed downregulation of CLDN1 at the mRNA and
protein levels under DGAT1-silencing conditions in another hep-
atoma cell line, HepG2, following DGAT1 silencing by lentivirus
shRNA transduction (Fig. 3G).
Forced expression of CLDN1 restoresHCVentry toDGAT1-
silenced cell lines. To verify whether the downregulation of
CLDN1 expression led to HCV entry impairment, we transfected
DGAT1-silenced cell lines with the CLDN1 gene and evaluated
HCV entry using HCVpp. After 72 h of the transfection, CLDN1
expression was observed by immunoblotting (Fig. 4A) and flow
cytometry (Fig. 4B). Importantly, the entry of all of the HCVpp
was restored in theCLDN1-expressingDGAT1-silenced cells (Fig.
4C). These results demonstrate that CLDN1 downregulation is
responsible for impairment of HCV entry into DGAT1-silenced
cells and that the reexpression of CLDN1 is sufficient to restore
HCV entry into these cells.
Expression of hepatocyte-specific genes is reduced in
DGAT1-silenced cell lines. In DGAT1-silenced cells, we exam-
ined the expression of hepatocyte nuclear factor 4 (HNF4) be-
cause this factor has been reported to be associated with CLDN1
expression inmice (32–34). In fact, HNF4 expression wasmark-
edly reduced in DGAT1-silenced cell lines at both the mRNA and
protein levels (Fig. 5A). HNF4 is a central regulator of hepato-
cyte differentiation and function (35, 36), and the expression of
other hepatocyte-specific genes, such as the albumin and 1-an-
titrypsin genes, was also decreased in the DGAT1-silenced cells
(Fig. 5B), suggesting that their differentiation status had been al-
tered by DGAT1 silencing. However, HNF4 expression was not
downregulated by the silencing of DGAT2 (Fig. 5C). We also ex-
amined temporal changes in DGAT1, HNF4, and CLDN1 ex-
pression during the establishment of a stable cell line following
lentivirus shRNA-DGAT1 transduction into Huh-7.5 cells.
DGAT1 expression was silenced at 10 days following transduc-
tion,whereas the expression ofHNF4 andCLDN1was preserved
(Fig. 5D). HNF4 expression then decreased gradually, followed
by a slow decrease in CLDN1 expression. Ultimately, the expres-
sion of both HNF4 and CLDN1 was markedly diminished at 45
days following transduction (Fig. 5D).
To verify whether DGAT1 silencing directly caused the down-
regulation of HNF4 and CLDN1, we transfected shRNA-
DGAT1-transduced cells with the shRNA-resistant DGAT1 gene
10 days after the transduction. Following the transfection,DGAT1
expression was restored, and expression of HNF4 and CLDN1
was maintained (Fig. 6A). In addition, intracellular lipid droplets
were restored by transfection (Fig. 6B). Furthermore, HCVpp en-
try was recovered by the restoration of DGAT1 expression (Fig.
6C). Next, we examined the requirement for the catalytic activity
of DGAT1 for the maintenance of CLDN1 and HNF4 expres-
sion. We constructed a catalytically inactive DGAT1mutant gene
(H415A) (11, 37) that was also shRNA resistant. Unlike the cata-
lytically active DGAT1, the catalytically inactive form did not
maintain the expression of CLDN1 andHNF4 (Fig. 6D). Collec-
tively, these results indicate that DGAT1 silencing causes HNF4
andCLDN1downregulation andHCV entry impairment and that
the loss of DGAT1 catalytic activity is important in this process.
As HNF4 was reported to upregulate CLDN1 expression in
mice (32, 33), we examined whether HNF4 downregulation was
responsible for the CLDN1 downregulation that was observed in
the DGAT1-silenced cells. In fact, HNF4 bound to the promoter
region of human CLDN1 in the ChIP assay (Fig. 6E and F). How-
ever, HNF4 silencing by siRNA (siHNF4) did not significantly
decrease CLDN1 expression (Fig. 6G and H). We also transfected
DGAT1-silenced cells with theHNF4 gene. For the transfection,
we used the gene encoding HNF41, which is a major isoform in
adult human hepatocytes (38, 39). However, CLDN1 expression
was not restored by this transfection (Fig. 6I). Taking these find-
ings together, we conclude that CLDN1 expression is not regu-
lated solely byHNF4 but also by other factors that are influenced
by DGAT1 silencing.
Exogenous palmitic acid treatment prevents downregula-
tion of CLDN1 and HNF4 expression after DGAT1 silencing.
Considering that DGAT1 regulates intracellular lipid homeostasis
(10) and our data showing that intracellular lipid droplets are
depleted in DGAT1-silenced cells (Fig. 1E), we hypothesized that
CLDN1 downregulationmight be attributed to a dysregulation of
intracellular fatty acid metabolism. Therefore, we examined the
effect of exogenous fatty acid treatment following DGAT1 silenc-
ing. We applied BSA-conjugated palmitic acid (C16:0) at a low
concentration to shRNA-DGAT1-transduced cells 10 days after
the transduction and continued the treatment for 17 days. The
expression of CLDN1 and HNF4 was preserved by palmitic acid
treatment, although DGAT1 expression was silenced (Fig. 7A).
Importantly, HCVpp entry was also recovered by palmitic acid
treatment (Fig. 7B). These results indicate that altered fatty acid
homeostasis in DGAT1-silenced cells is associated with CLDN1
downregulation, which leads to HCV entry impairment.
DISCUSSION
In the present study, we attempted to identify the effects of com-
plete, long-term silencing of DGAT1 on the whole life cycle of
HCV in Huh-7.5 cells. We demonstrated that CLDN1 downregu-
lation impairs HCV entry into DGAT1-silenced cell lines and that
histogram is presented (B). F, mean fluorescence intensity (MFI) of specific antibody staining; F0, MFI of isotype control antibody staining. Data are represen-
tative of three independent experiments. (C) mRNA levels of CD81, SR-B1, CLDN1, and OCLN in DGAT1-silenced cell lines were determined by real-time
quantitative PCR and standardized to -actin mRNA levels (n	 3). (D) CLDN1 protein expression in DGAT1-silenced cell lines was assessed by immunoblot-
ting. (E) Immunoblot analysis was performed to evaluate CLDN1 expression in the control and DGAT2 knockdown Huh-7.5 cell line after 40 days of shRNA
lentiviral transduction. Data are representative of two independent experiments. (F) Immunofluorescence stainingwas performed using anti-OCLN (green) and
anti-CLDN1 (red) in Caco-2, shRNA-control, and DGAT1-silenced Huh-7.5 cell lines, and images were analyzed by confocal microscopy. Merged images are
also presented. The scale bar represents 20 m. (G) A stably DGAT1-silenced HepG2 cell line was established by transduction with a lentivirus harboring
shRNA-DGAT1-1666. ThemRNA levels of DGAT1 and CLDN1were determined by real-time quantitative PCR (n	 3) (left graph), and the protein expression
levels of DGAT1 and CLDN1were assessed by immunoblotting (right blots). Bar graphs represent means SEM. * and **, P 0.001 and P 0.01, respectively,
compared to the control.
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this effect is associated with altered fatty acid homeostasis. How-
ever, these findings were made using the Huh-7.5 human hepa-
toma cell line and need to be confirmed in primary human hepa-
tocytes.
One of the main roles of DGAT1 is in catalyzing the final step of
triglyceride biosynthesis (5, 6). However, studies of knockout mice
have shown that DGAT1 deficiency does not result in elevated levels
of diacylglycerol or acyl coenzyme A (acyl-CoA) in the liver, heart,
muscle, andadipose tissue following the ingestionofhigh-fat diets (7,
40).Thesedata suggest thatDGAT1doesnot simply catalyze thefinal
step of triglyceride biosynthesis but is involved in the regulation of
intracellular lipid homeostasis. In fact, DGAT1 recycles the products
of triglyceride hydrolysis, which are partial glycerides, for triglyceride
synthesis. In addition, DGAT1 inhibition decreases the intracellular
lipid pool comprised of triglycerides, partial glycerides, and free fatty
acids in human liver-derived cells (10, 41). In the present study, a
low-dose exogenous palmitic acid treatment prevented the down-
regulation of CLDN1 and HNF4 expression in DGAT1-silenced
cells. These results show that expression of CLDN1 and HNF4 is
regulated by altered intracellular lipid homeostasis in DGAT1-si-
lenced cells and that the restoration of intracellular fatty acid levels by
exogenous palmitic acid rescued CLDN1 andHNF4 expression.
FIG 4 Forced expression of CLDN1 restores HCV entry to DGAT1-silenced cell lines. (A) CLDN1 protein expression was assessed by immunoblotting after
mock or CLDN1 transfection of DGAT1-silenced cell lines. (B) Surface expression of CLDN1was analyzed by flow cytometry aftermock or CLDN1 transfection
of DGAT1-silenced cell lines. Data are representative of three independent experiments. (C) HCV entry was assessed after mock or CLDN1 transfection of
DGAT1-silenced cell lines using HCVpp of various genotypes. Virus pseudoparticles harboring the VSV-G envelope glycoprotein served as a positive control.
HCVpp entry was determined by luciferase activity. Data are expressed as percentages of the shRNA-control cell line (n 	 4). The statistical analysis was
conducted for differences between the mock-transfected and CLDN1-transfected cells. Bar graphs represent means SEM. *, P 0.001.
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We also made a DGAT2-silenced cell line in this study. How-
ever, the expression of CLDN1 and HNF4 was not downregu-
lated in the DGAT2-silenced cells (Fig. 3E and 5C). DGAT2 also
catalyzes the final step of triglyceride synthesis, but recent reports
suggest that DGAT1 and DGAT2 play different roles in human
hepatocytes (10). DGAT2 is involved in the de novo synthesis of
triglycerides, whereas DGAT1 functions in the reesterification of
partial glycerides that are generated by intracellular lipolysis.
Moreover, DGAT2 encompasses 30% of the total DGAT activity
in human hepatocytes, whereas DGAT1 contributes the other
70% (10).
HNF4 is a central regulator of hepatocyte differentiation and
function (33, 34) and is a major transcription factor that regulates
the expression of genes that are involved in lipid homeostasis (42).
HNF4 is also known to regulate the expression of proteins that
are required for hepatic and intestinal tight junction assembly,
including CLDN1, in mice (30–32). A recent study demonstrated
the binding of HNF4 to the CLDN1 gene by an electrophoretic
mobility shift assay andChIP assay of themouse fetal liver (30). In
accordance with this previous report, our present data showed
that HNF4 bound to the promoter region of humanCLDN1 in a
ChIP assay (Fig. 6E and F). However, HNF4 silencing did not
significantly decrease CLDN1 expression (Fig. 6G and H), and
HNF41 transfection did not restore CLDN1 expression in
DGAT1-silenced cells (Fig. 6I). Taking these findings together, we
conclude that CLDN1 expression is not regulated solely by
HNF4 but also by other factors that are influenced by DGAT1
silencing.
A previous study has shown that DGAT1 is involved in the
assembly of HCV by facilitating the trafficking of the HCV core
protein to the lipid droplet (11). The authors suppressed DGAT1
activity by using a DGAT1 inhibitor or silenced DGAT1 expres-
sion by shRNA, but they observed no impairment ofHCV entry to
Huh-7.5 cells. The discrepancy between the studies may be ex-
plained by the duration of DGAT1 inhibition or silencing. The
earlier study involved the use of the DGAT inhibitor for a short
duration of approximately 72 h. In contrast, we used stable
DGAT1-silenced cell lines to study the long-term effects of
DGAT1 silencing. In fact, CLDN1 expression decreased gradually
in shRNA-DGAT1-transduced cells andwasmarkedly downregu-
FIG 5 Expression of hepatocyte-specific genes is reduced in DGAT1-silenced cell lines. (A) HNF4mRNA levels in DGAT1-silenced cell lines were determined
by real-time quantitative PCR (n	 3) (upper graph), and HNF4 protein expression was assessed by immunoblotting (lower blots). (B) mRNA expression of
representative hepatic differentiation markers in control and DGAT1-silenced cell lines. Data are standardized to -actin mRNA levels (n 	 3). Bar graphs
represent means SEM. *, P 0.001 compared to the control. (C) Immunoblot analysis was performed to evaluate HNF4 expression in control and DGAT2
knockdown Huh-7.5 cell lines after 40 days of lentivirus shRNA transduction. Data are representative of two independent experiments. (D) Huh-7.5 cells were
transduced with lentivirus harboring shRNA-DGAT1-1402, and temporal changes in protein expression were examined during the establishment of a stable cell
line. The cell pellets were harvested at days 10, 25, 32, and 45 after transduction and subjected to immunoblot analyses to detect DGAT1, HNF4, and CLDN1.
Data are representative of two independent experiments.
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FIG 6 Catalytically active DGAT1 is responsible for maintaining CLDN1 expression and the hepatocyte-specific phenotype in Huh-7.5 cells. (A) An shRNA-1402-
resistantDGAT1 gene was constructed by introducing 6 point mutations into the sequence that is recognized by the shRNA-1402 oligonucleotide without altering the
amino acid sequence. The shRNA-1402-resistant DGAT1 gene was transfected into shRNA-DGAT1-1402-harboring cells 10 days after transduction, and temporal
changes in protein expression were examined. The cell pellets were harvested at days 10, 31, and 45 after transduction with lentivirus harboring shRNA-DGAT1-1402
(days 0, 21, and 35 after the shRNA-1402-resistant DGAT1 transfection) and were subjected to immunoblot analysis to detect DGAT1, HNF4, and CLDN1. Data are
representative of two independent experiments. (B) Intracellular lipid droplet staining was performed using the BODIPY lipid probe 493/503 in cells that had been
transfected with mock or shRNA-resistant DGAT1. The scale bar represents 20 m. (C) HCV entry into DGAT1-silenced cell lines was assessed after mock or
shRNA-resistantDGAT1 transfection using JFH1HCVpp.Data are expressed as percentages of the pretransfected cell line (n	 3). Bar graphs representmeans SEM.
*, P 0.001. (D) Immunoblot analysis of DGAT1-silenced cell lines harboring a catalytically active or inactive DGAT1 gene was performed. A catalytically inactive
DGAT1-encoding plasmid was constructed by site-directed mutagenesis, replacing the histidine residue at position 415 (encoded by CAU) with alanine (encoded by
GCU), and the catalytically inactive DGAT1 gene was also shRNA resistant. We confirmed the sequence of the mutated construct, which was then used to transfect
Huh-7.5 cells on 10 days after DGAT1 silencing. Data are representative of two independent experiments. (E, F) The chromatin immunoprecipitation assay was
performed using anti-HNF4 antibody. In the schematic of the CLDN1 promoters, the putativeHNF4 binding site is shaded in gray, and the positions of the primers
for real-timeqPCRaredesignatedwith arrows (E).Real-timeqPCRanalysiswasperformedusingDNAprecipitatedby rabbit anti-HNF4 (clonenumberH171) (Santa
Cruz Biotechnology, Inc.) or IgG. Transthyretin (TTR) was used as a positive control (F). *, P 0.01 (n	 3). (G) Real-time qPCR analysis of HNF4 and CLDN1
expression in theHuh-7.5 cell linewas conducted after siHNF4 treatment.Data are standardized to-actinmRNA levels (n	 3). Bar graphs representmeans SEM.
*, P  0.001. (H) Immunoblot analysis of HNF4 and CLDN1 in the Huh-7.5 cell line was performed after siHNF4 treatment. Data are representative of two
independent experiments. (I) Immunoblot analysis ofHNF4 andCLDN1 inDGAT1-silenced cell lineswasperformedat 72hafter transfectionwithHNF41plasmid.
Data are representative of two independent experiments.
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lated only after long-term culturing for over 45 days (Fig. 5D). In
the present study, we also knocked out the DGAT1 gene by using
the TALEN technique to silence DGAT1 expression completely
and found no DGAT1 expression in the DGAT1-TALEN cell line
(Fig. 1C and D). Interestingly, DGAT1-TALEN transfection facil-
itated CLDN1 downregulation compared to shRNA-DGAT1
transduction in the process of stable cell line establishment (data
not shown). CLDN1 downregulation may be induced only by the
complete silencing of DGAT1, which could be achieved by a long-
term culture of shRNA-DGAT1-transduced cells or by highly ef-
ficient silencing with DGAT1-TALEN.
In the present study, we found that HCV RNA replication was
also slightly impaired in DGAT1-silenced cell lines (Fig. 2E). This
impairment can be partially attributed to the loss of lipid droplets
in these cells (Fig. 1E). In fact, recent studies have emphasized the
association of lipid droplets and HCV RNA replication (43). Fur-
ther research is required to clarify themanner bywhichHCVRNA
replication is influenced by intracellular fatty acid homeostasis.
In conclusion, our data demonstrate that complete, long-term
silencingofDGAT1causesCLDN1downregulationandthus inhibits
HCV entry and that CLDN1 downregulation is associated with al-
tered fatty acid homeostasis in the absence of DGAT1. Future re-
search isneeded toelucidate the exactmechanismsandconsequences
of CLDN1 downregulation in DGAT1-silenced hepatocytes.
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